Read Gene

Read Gene Days Payable Outstanding

The Days Payable Outstanding (DPO) of Read Gene (RDG.WA) as of Oct 21, 2026 is 570.49. In the previous year, Days Payable Outstanding (DPO) was 591.13 — a change of -3.49% (lower).

Days Payable Outstanding

570.49

YoY

-3.49%

Last updated:

Days Payable Outstanding (DPO) of Read Gene is 2025 570.49 . Days Payable Outstanding (DPO) of Read Gene was 2024 591.13 . It decreases by -3.49% lower compared to the previous year.

The Read Gene Days Payable Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Payable Outstanding
Date
Days Payable Outstanding
Jan 1, 2014
195.41 PLN
Jan 1, 2020
131.58 PLN
Jan 1, 2021
408.52 PLN
Jan 1, 2022
213.33 PLN
Jan 1, 2023
377.83 PLN
Jan 1, 2024
591.13 PLN
Jan 1, 2025
570.49 PLN
The Read Gene Days Payable Outstanding history
YEARDays Payable OutstandingYoY
570.49-3.49%
591.13+56.45%
377.83+77.11%
213.33-47.78%
408.52+210.48%
131.58-32.67%
195.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

Days Payable Outstanding (DPO) of Read Gene is 570.49 in 2025.

Days Payable Outstanding (DPO) of Read Gene changed from 591.13 to 570.49, representing a -3.49% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Days Payable Outstanding (DPO) Read Gene since 2006 – with annual values, charts, and detailed analysis.

DPO measures the average number of days a company takes to pay its suppliers. Higher DPO can improve cash flow but may strain supplier relationships.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Payable Outstanding (DPO)'s Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Payable Outstanding (DPO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Payable Outstanding (DPO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Read Gene

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Read Gene